NCT00552851

Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant

Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant: an Open-labelled, Prospective Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 4 (estimated)
• Sponsor: University of Wuerzburg · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year.

Conditions

• Acromegaly
• Heart Failure
• Hypertrophy, Left Ventricular

Interventions

Type	Name	Description
DRUG	pegvisomant	booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year

Timeline

• Start date: 2006-06-01
• Completion: 2010-12-01
• First posted: 2007-11-02
• Last updated: 2010-09-24

Locations

1 site across 1 country: Germany